ESR1 and metastatic neoplasm: ESR1 mutations are rarely acquired during adjuvant AI (21, 24) but are commonly detected after therapy for metastatic disease, suggesting that mechanisms of resistance to targeted therapy may be substantially different between the treatment of micrometastatic and overt metastatic cancer.